Viking Therapeutics (VKTX) Debt Ratio (2014 - 2018)
Viking Therapeutics (VKTX) posted Debt Ratio of 0.2 for Q1 2016, up 21.03% sequentially from 0.16 in Q4 2015.
Powered by 
Analysis
Viking Therapeutics (VKTX) Debt Ratio (2014 - 2018) Analysis & Trends
Viking Therapeutics has reported Debt Ratio for 2 years, with the latest figure at 0.2 in Q1 2016.
- Quarterly Debt Ratio changed N/A year-over-year to 0.2 in Q1 2016, while the trailing twelve-month figure through Mar 2016 was 0.2 (changed N/A YoY) and the FY2015 annual result came in at 0.16, changed N/A from the prior year.
- Debt Ratio grew to 0.2 in Q1 2016 per VKTX's latest filing, from 0.16 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.2 in Q1 2016 and troughed at 0.16 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Viking Therapeutics | 4.06 Bn | 4.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | 0.05 |
| Dec 31, 2017 | 0.16 |
| Sep 30, 2017 | 0.27 |
| Jun 30, 2017 | 0.21 |
| Dec 31, 2016 | 0.22 |
| Sep 30, 2016 | 0.17 |
| Jun 30, 2016 | 0.13 |
| Mar 31, 2016 | 0.20 |
| Dec 31, 2015 | 0.16 |
| Sep 30, 2015 | 0.10 |
| Jun 30, 2015 | 0.08 |
| Mar 31, 2015 | 0.11 |
| Dec 31, 2014 | 0.10 |